Presentation
Awaiting price reaction for this filing.
JB Pharma reported FY25 revenue of INR 3,918 crores, up 12% year-on-year, with domestic formulations growing 20% to INR 2,269 crores and international business growing 4% to INR 1,649 crores. Operating EBITDA crossed INR 1,000 crores for the first time, reaching INR 1,087 crores (up 16%) with margins improving 70 basis points to 27.7%. Profit after tax rose 19% to INR 660 crores, and the company turned net cash with INR 689 crores on the balance sheet versus INR 107 crores last year. ROCE improved to 32% from 27%, supported by strong operating cash flows at 83% of EBITDA. The company ranks #22 in IPM with 6 brands in the top 300, and its CDMO lozenge business is among the top 5 globally.
Strong all-round performance with margin expansion, cash build-up, and capital efficiency improvement is positive for shareholders. Management's guidance of sustained 200-400 bps outperformance versus IPM and operating margins in the 27%-29% range signals confidence in continued earnings growth.